SCHEMBL563056

SCHEMBL563056

CCC(N)(CC(C)C)C(=O)O

nearest known ligand 0.52

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 3/20 0.52
MEN1 O00255 2/20 0.52
KMT2A Q03164 2/20 0.52
ALDH1A1 P00352 1/20 0.52
THRB P10828 1/20 0.52
ARG1 P05089 3/20 0.44
ARG2 P78540 3/20 0.44
GRM2 Q14416 2/20 0.42
GRM3 Q14832 2/20 0.42
NOS3 P29474 1/20 0.39
NOS1 P29475 1/20 0.39
NOS2 P35228 1/20 0.39
SLC7A5 Q01650 1/20 0.33
ODC1 P11926 1/20 0.32
MMP8 P22894 1/20 0.32
CYP2D6 P10635 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3383450 1.00 CYP1A2 (0.52) CYP1A2MEN1KMT2AALDH1A1THRB
SCHEMBL497762 0.88 GRM2 (0.46) CYP1A2MEN1KMT2AALDH1A1THRB
SCHEMBL1301353 0.83 CYP1A2 (0.48) CYP1A2MEN1KMT2AALDH1A1THRB
SCHEMBL3100826 0.82 GRM2 (0.42) CYP1A2MEN1KMT2AALDH1A1THRB
SCHEMBL3100821 0.82 GRM2 (0.42) CYP1A2MEN1KMT2AALDH1A1THRB
SCHEMBL6518490 0.82 MEN1 (0.38) CYP1A2MEN1KMT2AALDH1A1THRB
SCHEMBL6518493 0.82 MEN1 (0.38) CYP1A2MEN1KMT2AALDH1A1THRB
SCHEMBL20221433 0.80 MEN1 (0.36) CYP1A2MEN1KMT2AALDH1A1THRB
SCHEMBL17143589 0.80 ODC1 (0.48) CYP1A2MEN1KMT2AALDH1A1THRB
SCHEMBL16222675 0.80 GRM2 (0.41) CYP1A2MEN1KMT2AALDH1A1THRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230127248-A1 PEPTIDOMIMETIC MACROCYCLES AND FORMULATIONS THEREOF AILERON THERAPEUTICS, INC. 2023-04-27 US disclosed
CN-114729006-A Cyclic peptide compounds having Kras inhibitory activity 中外制药株式会社 2022-07-08 CN disclosed
US-8492416-B2 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses UCB PHARMA, S.A. (BE) 2013-07-23 US disclosed
US-20120035239-A1 2-OXO-1-PYRROLIDINE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES UCB Biopharma SRL (BE) 2012-02-09 US disclosed
US-8034958-B2 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses UOB Pharma, S.A. (BE) 2011-10-11 US disclosed
US-20100222576-A1 2-Oxo-1-pyrrolidine derivatives, processes for preparing them and their uses UCB BIOPHARMA SPRL (BE) 2010-09-02 US disclosed
US-7692028-B2 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses UCB PHARMA, S.A. (BE) 2010-04-06 US disclosed
US-20080097109-A1 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses UCB BIOPHARMA SPRL (BE) 2008-04-24 US disclosed
US-7358276-B2 for treating neurological disorders such as epilepsy, neuropathic pain, bipolar disorder or migraine; 2-(2-oxo-4-propyl-1-pyrrolidinyl)butanamide; neuroprotective agent UCB, S.A. (BE) 2008-04-15 US disclosed
EP-1447399-B9 \"2-oxo-1-pyrrolidine derivative and its pharmaceutical uses\ UCB SA (BE) 2006-10-18 EP disclosed
US-6911461-B2 For treating epilepsy, epileptogenesis, seizure disorders, convulsions, bipolar disorders, mania, depression, anxiety, migraine, neuralgia, chronic pain, neuropathic pain, cerebral ischemia, cardiac arrhythmia, myotonia, cocaine abuse UCB, S.A. (BE) 2005-06-28 US disclosed
US-6806287-B2 NEUROLOGICAL DISORDERS; SUCH AS 2-(4-(2,2-DIFLUOROVINYL)-2-OXOPYRROLIDINYL)BUTANAMIDE UCB, S.A. (BE) 2004-10-19 US disclosed
EP-1452524-A1 \"2-oxo-1-pyrrolidine derivative and its pharmaceutical uses\ UCB, S.A. (BE) 2004-09-01 EP disclosed
US-6784197-B2 SUCH AS (2S)-2-((4S)-4-(2,2-DIFLUOROVINYL)-2-OXOPYRROLIDINYL) BUTANAMIDE; ANTIEPILEPTIC AGENTS; ANTICONVULSANTS UCB S.A. (BE) 2004-08-31 US disclosed
EP-1447399-A1 \"2-oxo-1-pyrrolidine derivative and its pharmaceutical uses\ UCB, S.A. (BE) 2004-08-18 EP disclosed
US-20040116507-A1 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses UCB Biopharma SRL (BE) 2004-06-17 US disclosed
US-20040087646-A1 2-Oxo-1-pyrrolidine derivatives, processes for preparing them and their uses UCB BIOPHARMA SPRL (BE) 2004-05-06 US disclosed
US-20030120080-A1 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses UCB Biopharma SRL (BE) 2003-06-26 US disclosed
EP-1265862-A2 2-OXO-1-PYRROLIDINE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES UCB, S.A. (BE) 2002-12-18 EP disclosed
WO-2001062726-A2 2-OXO-1-PYRROLIDINE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES UCB, S.A. (BE) 2001-08-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230127248-A1 PEPTIDOMIMETIC MACROCYCLES AND FORMULATIONS THEREOF MDM2, TP53, TP53BP1 CYP1A2 4431/4885MEN1 567/4885KMT2A 3419/4885
US-20080097109-A1 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses CYP1B1, OGDH, CYP1A2 CYP1A2 3/4885MEN1 1354/4885KMT2A 1072/4885
US-20100222576-A1 2-Oxo-1-pyrrolidine derivatives, processes for preparing them and their uses CYP1B1, OGDH, CYP1A2 CYP1A2 3/4885MEN1 1354/4885KMT2A 1072/4885
US-20120035239-A1 2-OXO-1-PYRROLIDINE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES CYP1B1, OGDH, CYP1A2 CYP1A2 3/4885MEN1 1354/4885KMT2A 1072/4885
US-20030120080-A1 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses CYP1B1, CYP1A2, OGDH CYP1A2 2/4885MEN1 1333/4885KMT2A 1039/4885
US-20040087646-A1 2-Oxo-1-pyrrolidine derivatives, processes for preparing them and their uses CYP1B1, CYP1A2, OGDH CYP1A2 2/4885MEN1 1186/4885KMT2A 1101/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.